Spironolactone and Prevention of Calcineurin Inhibitor Toxicity in Kidney Transplant Recipients

NCT01021943 ↗

Phase 2 Suspended 40 enrolled Instituto Nacional de Cardiologia Ignacio Chavez

RandomizedParallel-groupDouble-blindTreatment

Summary

The main objective of this study is to assess the effect of spironolactone on interstitial fibrosis in kidney transplant recipients receiving calcineurin inhibitors

Timeline

Start: 2009-11
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Spironolactone	Small molecule	25 mg	—

Indications

No indication recorded.